Drs. George Lenz and Loretta Nastoupil discuss phase 3 FRONTMIND study

From EHA 2026, Dr. Loretta Nastoupil interviews Dr. Georg Lenz on the phase 3 FRONTMIND study, a randomised, double-blind, placebo-controlled study that evaluated tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma. The post Drs. George Lenz and Loretta Nastoupil discuss phase 3 FRONTMIND study appeared first on…